Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Multiple Myeloma 90Neoplasms, Plasma Cell 28Central Nervous System Neoplasms 11Recurrence 10Glioblastoma 10Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Gliosarcoma 8Melanoma 6Lung Neoplasms 6Leukemia 6Glioma 6Carcinoma, Non-Small-Cell Lung 6Waldenstrom Macroglobulinemia 5Prostatic Neoplasms 5Lymphoma, Mantle-Cell 5Myeloproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Immunoglobulin Light-chain Amyloidosis 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Astrocytoma 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Myelodysplastic-Myeloproliferative Diseases 3Myelodysplastic Syndromes 3Medulloblastoma 3

Interventions

Radiotherapy 2Radiosurgery 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2sacubitril and valsartan sodium hydrate drug combination 1icotinib 1dostarlimab 1beta Carotene 1avelumab 1alpha-Tocopherol 1Varenicline 1Tyrosine Kinase Inhibitors 1Trastuzumab 1Tobacco Use Cessation Devices 1Therapeutics 1Thalidomide 1Temozolomide 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Semen Analysis 1Registries 1Probiotics 1Patient Reported Outcome Measures 1Panitumumab 1Nicotine Chewing Gum 1Myofascial Release Therapy 1Megestrol Acetate 1Isotretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Second Primary × Thalidomide × Clear all
NCT03777930 2018-12-19

The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol

Shenzhen Fifth People's Hospital

Phase 4 Unknown
200 enrolled
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡